Wegovy Pill’s Gulf Debut Puts Novo Nordisk’s Global Ambitions to the Test Amid Competitive Pressure

Novo Nordisk expands oral Wegovy to UAE, targeting a vast untapped obesity market. Shares remain under pressure from competition and pricing headwinds despite the milestone.

Novo Nordisk has taken its oral weight-loss drug Wegovy beyond US borders for the first time, launching the tablet in the United Arab Emirates on 3 June 2026. The move marks a critical step in the Danish drugmaker’s strategy to diversify geographically at a time when its shares remain under severe pressure from competition and pricing headwinds at home.

The UAE offers a compelling growth story. Nearly 7.5 million people in the country are projected to be overweight or obese by 2035, and roughly one in three adults already lives with obesity today. Yet only 2% of patients in the region currently receive GLP-1 therapies, leaving a vast untapped market for the oral formulation. The pill’s key logistical advantage — it requires no cold chain, unlike the injectable version — allows Novo Nordisk to use standard pharmaceutical distribution channels, simplifying entry into the Gulf.

Approval from the Emirates Drug Establishment covers not just weight management but also the reduction of major cardiovascular events such as heart attacks and strokes, a distinction that sets the Wegovy tablet apart from competing oral options. The clinical underpinnings come from the OASIS-4 study, in which patients taking 25 mg of oral semaglutide lost an average of 17% of their body weight, and one in three achieved a loss of 20% or more.

Stock Momentum Remains Fragile

Despite the product milestone, the equity story continues to struggle. Shares in Novo Nordisk slipped 17.82% year-to-date and are down 41.21% over the past twelve months. In German trading the stock stood at €36.72, a level that is 48% below its 52-week high. A modest premarket gain of 0.3% on the launch day failed to change the broader picture.

Goldman Sachs raised its price target on Novo Nordisk from 263 to 305 Danish kroner but kept a “Neutral” rating. The bank’s message is cautious: the valuation has become somewhat more attractive, but no outright bullish call is warranted. Technically, the stock has moved back above its 50-day moving average, yet it remains well below the 200-day line — a classic sign that any recovery is tentative.

Revenue from the Pill Is Modest but Growing

The oral Wegovy generated 2.26 billion Danish kroner (about $355 million) in first-quarter 2026 revenue, accounting for roughly 3% of Novo Nordisk’s total sales. Since January, more than two million prescriptions have been written globally. The tablet’s contribution is still small, but the launch in the UAE is designed to accelerate uptake beyond the US, where the pill debuted in January.

The company’s market capitalisation stands at approximately $190 billion, giving it a price-to-earnings ratio of 10.07 — cheap by historical standards for Novo Nordisk, but reflective of the sharp sell-off.

Eli Lilly Looms Large on the Competitive Landscape

The biggest overhang remains Eli Lilly. Novo Nordisk was the global leader in obesity products by volume in 2025 with a 59.6% share, and it held 45.8% of the GLP-1 market for type 2 diabetes by value. Yet in the US, Lilly has pulled ahead: Novo Nordisk’s share of US semaglutide prescriptions had slipped to around 37.4% by early June. Lilly’s Mounjaro overtook Ozempic as the top-selling GLP-1 drug in the second quarter of 2025, and its obesity shot Zepbound is gaining ground. Meanwhile, Novo Nordisk’s own pipeline hopeful CagriSema recently missed efficacy expectations in a head-to-head context.

The pressure from Lilly is one reason Novo Nordisk is pushing into new international markets. Emil Kongshøj Larsen, head of international operations, has described the expansion as an “all-in” strategy. Additional country launches are planned for the second half of 2026, pending local regulatory approvals and health-system readiness. A key decision from the European Medicines Agency on European approval is still awaited.

ADA Conference Looms as the Next Catalyst

Investors will now look to the American Diabetes Association conference, running from 5 to 8 June, where Novo Nordisk is expected to present further pipeline data. The market is hungry for evidence that the company can regain momentum in the GLP-1 race beyond simply defending its existing footprint.

The financial firepower to invest is there: a gross margin of 81% and a net margin of 33% leave plenty of room for R&D and commercial expansion. Yet large institutional holders are becoming more selective. Peapack Gladstone Financial Corp cut its position by 25.5% in the fourth quarter, leaving it with 73,091 shares valued at roughly $3.72 million.

For now, the Wegovy tablet’s international rollout offers a new growth vector. But until that translates into meaningful revenue acceleration and market-share stabilisation against Eli Lilly, the stock’s fragility is likely to persist.